Patient-level adverse event data were analyzed for 4400 patients in randomized placebo-controlled trials of the antipsychotic risperidone in schizophrenia, bipolar disorder, and Alzheimer’s disease psychosis.

Adverse events of risperidone that were class specific (to the class of dopamine D2 antipsychotics) showed notable between-diagnosis differences in prevalence (e.g., lower for Alzheimer’s disease psychosis; higher for autism), suggesting that the diagnostic indication may have an important effect on the cumulative class-specific side-effect burden.